Dr. Adam Fein PhD
Founder & President, PEMBROKE CONSULTING INC
Member of the Healthcare Council
Council Member Biography
Adam Fein, PhD, is the Founder and President of Pembroke Consulting, Inc., a Philadelphia-based management advisory and business research firm. Dr. Fein is one of the country's foremost experts on pharmacy economics and the pharmaceutical supply chain. He provides strategic advisory services to a diverse mix of clients, including pharmaceutical manufacturers, technology companies, law firms, trade associations, institutional investors, and other participants in the U.S. health care system. Dr. Fein blogs at DrugChannels.net, which is widely read and cited throughout the pharmaceutical, pharmacy, and managed care industries. The media frequently seek his industry expertise, and he has been quoted in such leading national publications such as The Wall Street Journal, The New York Times, Pharmaceutical Executive, Drug Benefit News, and many others. Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania. (This is me - Update Profile)
Employment History
- 1997 - Unspecified
- Founder & President, PEMBROKE CONSULTING INC
GLG NewsSM Analyses by Adam Fein
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
July 26, 2011
Megadeal Unites Drug Rivals | online.wsj.com
I give the Express Scripts / Medco Health Solutions deal a 60% chance of being approved by the Federal Trade Commission. I think it’s going to be a very tough fight for antitrust approval, but perhaps not for the reasons you think. The Agreement and Plan of Merger filed on Friday gives us a peek at the companies’ strategy for clearing the antitrust hurdles. But note that there is no termination fee if the companies don’t get antitrust clearance.
-
ESRX-MHS: Strategic and Market Analysis
July 25, 2011
The Express Scripts / Medco Health Solutions deal makes sense given the dynamics of the PBM industry. At the same time, a successful transaction would signal the end of the PBM industry's major growth opportunities and the transition to a more mature, highly consolidated market. The post-2015 world looks much less rosy for PBMs as the generic wave crests and the government crowds out private payers.
-
What's Behind Teva's Cephalon Deal
May 3, 2011
Teva to Buy Cephalon in $6.8b Transaction | www.bloomberg.com
This is a great, albeit expensive, strategic move by Teva. Management clearly recognizes the business model problem looming ahead for the generic drug business. The deal boosts Teva's brand business while maintaining a broadly diversified revenue base, positioning Teva as the "anti-Pfizer."The pharma industry of tomorrow will be about expensive drugs for small patient populations and cheap drugs for large populations. I wonder how many manufacturers will be ready.
-
2011 Part D Market Share: A Win for Humana and Walmart
April 29, 2011
Next Monday, Humana will report results for the first quarter of 2011. Based on my independent analysis of CMS data on Medicare Part D Prescription Drug Plans (PDPs), the company will have a lot to brag about next week for its Retail segment: Humana had a net gain of about 570,000 PDP enrollees, more than any other organization in 2011. The Humana Walmart-Preferred Rx Plan, a preferred pharmacy network PDP launched in October 2010, is now the fifth-largest PDP in the U.S.
-
Express Scripts' Disruptive Specialty Strategy
April 14, 2011
Express Scripts is ahead of its PBM peers with an innovative and risky strategy for absorbing the buy-and-bill specialty drug spending from health care providers. If successful, the company will become the clear leader in a big new addressable market for PBM services. It also puts them on a collision course with AmerisourceBergen and McKesson for control over specialty channels to physician offices and clinics.
GLG Study Groups with Adam Fein(?)
GLG Live Meetings with Adam Fein(?)
Adam Fein has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.